Literature DB >> 20212962

Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

.   

Abstract

Entities:  

Year:  1999        PMID： 20212962      PMCID： PMC2827759     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  20 in total

Review 1.  Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

Authors:  H C Meissner; R C Welliver; S A Chartrand; B J Law; L E Weisman; H L Dorkin; W J Rodriguez
Journal:  Pediatr Infect Dis J       Date:  1999-03       Impact factor: 2.129

2.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

3.  Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation.

Authors:  C K Cunningham; J A McMillan; S J Gross
Journal:  Pediatrics       Date:  1991-09       Impact factor: 7.124

4.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Evidence-based medicine.

Authors:  D W MacPherson
Journal:  Can Commun Dis Rep       Date:  1994-09-15

6.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

7.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors:  K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129

8.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors: 
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

9.  Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1998-11       Impact factor: 7.124

10.  Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus.

Authors:  P Madge; J Y Paton; J H McColl; P L Mackie
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321
View more
  12 in total

1.  Use of palivizumab in children with congenital heart disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

2.  Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.

Authors:  S L Lee; P Etches; J L Robinson
Journal:  Paediatr Child Health       Date:  2001-10       Impact factor: 2.253

3.  Preventing hospitalizations for respiratory syncytial virus infection.

Authors:  Joan L Robinson; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2015 Aug-Sep       Impact factor: 2.253

4.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

5.  Prophylaxis of respiratory syncytial virus in Canada in 2003.

Authors:  Joan L Robinson; Bonita E Lee
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

6.  The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.

Authors:  Anna Banerji; Vladimir Panzov; Michael Young; Bonita E Lee; Muhammad Mamdani; B Louise Giles; Marguerite Dennis; Johanne Morel; Danny Bisson; Bosco A Paes; Charles Hui; Jim Mahony
Journal:  Can Respir J       Date:  2013-12-23       Impact factor: 2.409

7.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

8.  Compliance with RSV prophylaxis: Global physicians' perspectives.

Authors:  Kari S Anderson; Victoria M Mullally; Linda M Fredrick; Andrew L Campbell
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.

Authors:  Dong-Hoon Chung; Blake P Moore; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; Melinda I Sosa; Subramaniam Ananthan; E Lucile White; Fuli Jia; Colleen B Jonsson; William E Severson
Journal:  Virol J       Date:  2013-01-10       Impact factor: 4.099

Review 10.  Respiratory syncytial virus infections in infants affected by primary immunodeficiency.

Authors:  Marcello Lanari; Silvia Vandini; Maria Grazia Capretti; Tiziana Lazzarotto; Giacomo Faldella
Journal:  J Immunol Res       Date:  2014-06-25       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.